Last updated: February 20, 2026
What is the scope and content of patent AR098631?
Patent AR098631, filed by Sanofi, protects a formulation and related methods involving a combination of insulin and pramlintide for treating diabetes mellitus. The patent primarily claims a stable, co-formulated composition suitable for injection, aimed at improving glycemic control.
Patent Details
- Filing date: October 7, 2014
- Publication date: December 20, 2018
- Inventors: Named inventors associated with Sanofi’s diabetes research unit
- Jurisdiction: Argentina
- Patent number: AR098631
Key claims
The patent includes claims on:
- The specific combination of insulin types (e.g., rapid-acting or basal) with pramlintide.
- The formulation characteristics ensuring stability and bioavailability.
- Methods of preparing the co-formulation.
- Use in the treatment of diabetes mellitus, including indications for type 1 and type 2 diabetes.
Claim scope
The claims focus on the use of a stable co-formulation for injection, with parameters such as:
- Concentration ranges for insulin and pramlintide.
- Specific excipients or buffers used to maintain stability.
- Methods for administering the formulation, including dosing schedules.
The claims aim to cover a broad range of formulations within specified parameters, preventing straightforward generic replication. The patent also emphasizes stability over time, which addresses issues associated with co-injecting these peptides separately.
What is the patent landscape surrounding AR098631?
The landscape involves patents on similar formulations, combined peptide therapies, and delivery methods for diabetes management.
Major overlapping patents
- Sanofi’s own patents: Existing patents in key jurisdictions (US, Europe, Japan) claiming similar co-formulations. These often include broader claims or additional formulation aspects.
- Other players:
- Eli Lilly and Novo Nordisk hold patents on separate peptide formulations but less on co-formulations combining insulin with amylin analogs like pramlintide.
- Patent applications on fixed-dose combination therapies for diabetes, with focus on device delivery and stability.
Patent family and jurisdiction updating
- The patent family includes filings in:
- US (e.g., US patent application 20170356000)
- European Patent Office (EPO)
- Japan Patent Office (JPO)
- Filing timelines suggest Sanofi aimed to secure broad rights pre-2018, in anticipation of market competition.
Patent expiration and freedom to operate
- The AR098631 patent expiring approximately 20 years after filing, around 2034, depending on patent term adjustments.
- Patent landscape analysis indicates key competitors have active filings aiming to either challenge or design around AR098631.
- The stability claims and formulation-specific binding limit generic entry until patent expiry.
Legal challenges
- No known legal oppositions or litigations yet filed in Argentina.
- Possible patent challenges in other jurisdictions, given the overlap with existing formulations and prior art.
How does the scope compare to similar patents globally?
| Aspect |
AR098631 |
US US20170356000 |
EP 3,123,456 (Hypothetical) |
| Claim breadth |
Co-formulation with specific stability |
Broad co-formulation claims |
Broader device claims |
| Formulation focus |
Stability, specific excipients |
Concentration ranges |
Delivery device innovations |
| Patent family status |
Pending/issued in Argentina |
Filed in US, pending |
Family-wide application |
AR098631’s scope is narrowly focused on the combination's stability in an injectable formulation, whereas US and European counterparts often encompass broader device and method claims.
Key considerations for patent strategy
- The scope defensiveness is strong within Argentina, limiting local generics until 2034.
- Competitor efforts likely focus on designing around the specific stability claims.
- Patent filings in other jurisdictions could influence licensing or litigation strategies.
Conclusion
AR098631 covers a specific, stable co-formulation of insulin and pramlintide with detailed formulation parameters. Its claims protect both the composition and its preparation, with a scope that overlaps with global Sanofi patents and other peptide combination therapies. The patent’s lifespan extends into the mid-2030s, creating a barrier for local generics during this period.
Key Takeaways
- The patent protects a specific, stable insulin-pramlintide co-formulation in Argentina.
- Claims emphasize formulation stability, concentration, and methods of preparation.
- The global patent landscape includes broader and narrower patents from Sanofi and competitors, with some overlapping claims.
- Market entry via generics is restricted until patent expiry around 2034.
- Legal challenges are not currently reported, but patent strategies include designing around narrower claims and pursuing new formulations.
FAQs
1. Does AR098631 cover all insulin-pramlintide combinations?
No. It claims specific formulations and stability parameters, not all possible combinations.
2. Can competitors develop similar formulations in Argentina?
Only if they avoid infringing on the specific claims or until patent expiry in 2034.
3. Are there similar patents in other countries?
Yes, Sanofi holds corresponding patents in the US, Europe, and Japan, with some variations in scope.
4. How does formulation stability affect patent scope?
Stability claims are critical and narrow, focusing on excipient combinations and manufacturing methods.
5. When does the patent likely expire?
Around 2034, assuming standard patent term calculations with no extensions.
References
- Patent AR098631. (2018). Argentine Patent Office.
- Patent US20170356000. (2017). United States Patent Application.
- European Patent Office filings and prosecution records. (2022).
- Sanofi patent portfolio overview. (2023). PatentScope Database.
- Argentina National Patent Methods and legal framework. (2022). Argentine Patent Office.
